Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials
Racial/ethnicity differences in endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials
复制标题
DOI：
10.1016/j.urolonc.2019.10.015
复制
发表时间：
2020-03-01
影响因子：
2.7
通讯作者：
Berry, Donna L.
中科院分区：
文献类型：
--
作者：
Quoc-Dien Trinh;Hong, Fangxin;Berry, Donna L.
目的：在美国男性中，局限性前列腺癌的发病率和治疗选择因人种/种族而异。我们假设，有组间差异的影响力的价值观和偏好相关的治疗decisions.Methods：我们分析了样本2多中心，随机试验的患者个人资料前列腺（P3 P）I和II的决策援助，第一组比较其他人口和决策变量卡方检验。然后使用分层（P3 P I vs. II）logistic回归评估种族/民族与14种生活方式因素、当前或未来症状或其他重要因素对决策的中度或强烈影响之间的单变量关联。多变量分层Logistic回归与向后变量选择被用来进一步估计影响因素和种族/ethnication.Results之间的关联：有494和392参与者在P3 P I和P3 P II，分别与40西班牙裔，168非西班牙裔黑人，637非西班牙裔白色，19人和6人失踪。年龄（P = 0.0001），教育（P < 0.0001），婚姻状况（P < 0.0001），收入（P < 0.0001），互联网信息使用（P < 0.0001）和决策控制偏好在种族/民族之间存在显著差异。在调整分析中，我们发现年龄对决策的影响存在种族/民族差异。（非西班牙裔黑人（NHB）vs.非西班牙裔白色（NHW）OR：0.56 95%CI 0.38-0.85 P = 0.002），宗教/灵性（NHB vs. NHW OR：3.2095%CI1.95-5.26，P < 0.0001），未来膀胱功能（NHB与NHW OR：0.5795%CI 0.35-0.90，P = 0.04），未来从事娱乐的能力（NHB vs. NHW OR：0.5495%CI 0.34- 0.86，P = 0.02），以及一个著名的前列腺癌患者的故事（NHB vs. NHW OR：2.11 95%CI 1.30- 3.43，P = 0.007）。结论：我们的研究结果表明种族/民族差异的影响潜在的治疗选择。更好地理解这些影响可能有助于我们向患者提供有关治疗选择的重要信息，并解决差异。(C)2019爱思唯尔公司All rights reserved.
Objective: Rates and choice of treatment for localized prostate cancer vary according to race/ethnicity in American men. We hypothesized that there were group differences in influential values and preferences related to treatment decisions.Methods: We analyzed samples from 2 multicenter, randomized trials of the Patient Profile-Prostate (P3P) I and II decision aid, first comparing the groups on other demographic and decisional variables using Chi-square tests. Stratified (P3P I vs. II) logistic regression was then used to assess the univariate association between race/ethnicity and endorsement of moderate-or-strong influence of 14 lifestyle factors, current or future symptoms, or important others on the decision. A multivariable stratified logistic regression with backward variable selection was used to further estimate the association between influential factors and race/ethnicity.Results: There were 494 and 392 participants in P3P I and P3P II, respectively, with 40 Hispanic, 168 non-Hispanic black, 637 nonHispanic white, 19 others and 6 missing. Age (P = 0.0001), education (P < 0.0001), marital status (P < 0.0001), income (P < 0.0001), Internet use for information (P < 0.0001) and decisional control preference were significantly different across racial/ethnic groups. In adjusted analyses, we saw racial/ethnic differences in the decisional influence of age (Non-Hispanic Black (NHB) vs. Non-Hispanic White (NHW) OR: 0.56 95%CI 0.38-0.85 P = 0.002), religion/spirituality (NHB vs. NHW OR: 3.2095%CI1.95-5.26, P < 0.0001), future bladder function (NHB vs. NHW OR: 0.5795%CI 0.35-0.90, P = 0.04), future ability to engage in recreation (NHB vs. NHW OR: 0.5495%CI 0.34- 0.86, P = 0.02), and a story of a famous person with prostate cancer (NHB vs. NHW OR: 2,11 95%CI 1.30- 3.43, P = 0.007). No interactions were found.Conclusion: Our results suggest racial/ethnic differences for influences underlying treatment choice. Better understanding these influences may help us present salient information about treatment options to patients and address disparities. (C) 2019 Elsevier Inc. All rights reserved.